Adagene partners with Incyte for cancer drug combination study
Go back to Adagene partners with Incyte for cancer drug combination study| (NASDAQ: ADAG) | Delayed: 3.82 -0.12 (3.05%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $3.94 | 52 Week High | $ | |||
| Open | $3.88 | 52 Week Low | $ | |||
| Day High | $4.09 | P/E | N/A | |||
| Day Low | $3.75 | EPS | $ | |||
| Volume | 263,171 | |||||
| Incyte Genomics, Inc. (NASDAQ: INCY) | Delayed: 114.23 -2.48 (2.12%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $116.71 | 52 Week High | $118.49 | |||
| Open | $115.97 | 52 Week Low | $55.00 | |||
| Day High | $116.02 | P/E | N/A | |||
| Day Low | $113.80 | EPS | $-0.56 | |||
| Volume | 1,480,994 | |||||
